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Background and Aims: Fibrosis staging by non-invasive tests is essential in non-alcoholic fatty liver disease (NAFLD). Measurement of liver stiffness by transient elastography (TE) is a well-established method for liver fibrosis assessment in NAFLD. We have previously shown that macrophage marker sCD163 is an independent predictor for fibrosis in NAFLD, and that combining sCD163 with e.g. NAFLD Fibrosis score improves the precision. In the present study we tested
whether the combination of macrophage markers and TE improves fibrosis prediction compared to the individual parameters.
Method:We measured macrophage markers soluble CD163 (sCD163) and mannose receptor (sMR) using in-house ELISA assays in two independent cohorts from Italy (n = 141) and Sweden (n = 70) with biopsy-proven NAFLD and available TE.
Results: In the Italian cohort, TE and sCD163 showed similar moderate associations with liver fibrosis (rho = 0.56, p < 001 and rho = 0.45, p < 0.001, respectively). TE had an area under the Receiver Operating Characteristics curve (AUROC) (with 95% CI) for F2 fibrosis: 0.79 (0.72–0.87), F3: 0.81 (0.73–0.89), F4: 0.95 (0.90–1.0). sCD163 also predicted fibrosiswell [F2: 0.71 (0.63–0.80), F3: 0.82 (0.74–0.90), F4: 0.89 (0.76–1.0)]. However, combining sCD163 and TE did not improve the AUROCs significantly [F2: 0.79 (0.72–0.87), F3: 0.85 (0.78–0.92), F4: 0.97 (0.93–1.0)]. In the Swedish cohort, TE showed a closer association with fibrosis (rho = 0.73, p < 0.001) than sCD163 (rho = 0.42, p < 0.001) and sMR (rho = 0.39, p < 0.001). TE predicted fibrosis well [F2: 0.88 (0.80–0.97), F3: 0.90 (0.83–0.97), F4: 0.87 (0.78–0.96)], whereas sCD163 did not (best AUROC 0.75). sMR showed a better prediction [F2: 0.68 (0.56–0.81), F3: 0.82 (0.71–
0.92), F4: 0.79 (0.66–0.93)], but the addition of sMR did not further improve the prediction of fibrosis by TE.
Conclusion: In these cohorts of NAFLD patients, TE was superior to macrophage markers for fibrosis prediction and in contrast to our hypothesis the addition of these markers to TE did not improve its predictive capability.

